Harmony Biosciences Holdings Inc
HRMY
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.1B
Close$
Share Statistics
| Market cap | $2.10 Billion |
|---|---|
| Enterprise Value | $1.71 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.76 |
| Beta | 1.01 |
| Outstanding Shares | 57,876,756 |
Return
| Return on Equity | 18.14% |
|---|---|
| Return on Assets | 13.20% |
| Return on Invested Capital | 21.37% |
Valuation & Multiples
| P/E Ratio | 11.54 |
|---|---|
| PEG | 12.88 |
| Price to Sales | 2.26 |
| Price to Book Ratio | 2.13 |
| Enterprise Value to Revenue | 1.78 |
| Enterprise Value to EBIT | 7.02 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.96
Average shareholder expectationRevenue Estimate
$250.77 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$1.11
Average shareholder expectationRevenue Estimate
$274.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 99.11% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.92%▼ 93.42% |
|---|---|
| Total Invested | $20.89M▼ 98.95% |
| Investors Holding | 23▼ 313.00% |
ESG Score
No data
About Harmony Biosciences Holdings Inc
150 employeesHarmony Biosciences Holdings, Inc. operates as a pharmaceutical company. The Company focuses on the research, drug development, and treatment for neurologic disorder of sleep-wake state instability. Harmony Biosciences Holdings serves patients in the United States.